PRME

Prime Medicine, Inc.

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Prime Medicine, Inc. (PRME) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Profitability (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
C
Factor Score 2.3 / 5.0
Growth
B
Factor Score 3.3 / 5.0
Profitability
D+
Factor Score 1.6 / 5.0
Momentum
B+
Factor Score 3.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -5.0
EV / EBITDA -4.7
Rev Growth YoY 243.9%
Gross Margin 0.0%
Price Return 3M 34.7%
Price Return 12M 20.3%
Catalyst Signal 0.00
Market Cap $774.5M
TTM Revenue $7.1M
Price / Sales 109.7
ROE -207.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C (2.3) B (3.3) D+ (1.6) B+ (3.7) C+ (2.6) C+ (2.7)
2026-11-07 D+ (1.7) C (2.2) D- (1.0) B (3.4) C+ (2.7) C (2.2)
2026-10-31 D+ (1.6) C- (2.1) D- (1.0) B- (2.9) C+ (2.7) C- (2.1)
2026-10-24 C- (2.0) C- (2.1) D- (0.9) C+ (2.6) C+ (2.6) C- (2.0)
2026-10-17 C- (2.1) C- (2.1) D- (0.9) C (2.5) C+ (2.6) C- (2.0)
Page 1 of 5